{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:48:59Z","timestamp":1790153339915,"version":"4.0.1"},"reference-count":50,"publisher":"The Company of Biologists","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,6,15]]},"abstract":"<jats:p>Several human genetic diseases that affect striated muscle have been modeled by creating knockout mouse strains. However, many of these are perinatal lethal mutations that result in death from respiratory distress within hours after birth. As the diaphragm muscle does not contract until birth, the sudden increase in diaphragm activity creates permanent injury to the muscle causing it to fail to meet respiratory demands. Therefore, the impact of these mutations remains hidden throughout embryonic development and early death prevents investigators from performing detailed studies of other striated muscle groups past the neonatal stage. Glycogen storage disease type II (GSDII), caused by a deficiency in acid \u03b1-glucosidase (GAA), leads to lysosomal accumulation of glycogen in all cell types and abnormal myofibrillogenesis in striated muscle. Contractile function of the diaphragm muscle is severely affected in both infantile-onset and late-onset individuals, with death often resulting from respiratory failure. The knockout mouse model of GSDII survives well into adulthood despite the gradual weakening of all striated muscle groups. Using this model, we investigated the delivery of recombinant adeno-associated virus (rAAV) vectors encoding the human GAA cDNA to the developing embryo. Results indicate specific high-level transduction of diaphragm tissue, leading to activity levels up to 10-fold higher than normal and restoration of normal contractile function. Up to an estimated 50 vector copies per diploid genome were quantified in treated diaphragms. Histological glycogen staining of treated diaphragms revealed prevention of lysosomal glycogen accumulation in almost all fibers when compared with untreated controls. This method could be employed with disease models where specific rescue of the diaphragm would allow for increased survival and thus further investigation into the impact of the gene deletion on other striated muscle groups.<\/jats:p>","DOI":"10.1242\/dev.01169","type":"journal-article","created":{"date-parts":[[2004,5,28]],"date-time":"2004-05-28T22:23:32Z","timestamp":1085783012000},"page":"3007-3019","source":"Crossref","is-referenced-by-count":64,"title":["Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease"],"prefix":"10.1242","volume":"131","author":[{"given":"Mary","family":"Rucker","sequence":"first","affiliation":[{"name":"Powell Gene Therapy Center, and Departments of Molecular Genetics and Microbiology and Pediatrics, University of Florida College of Medicine,Gainesville, Florida 32610, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Thomas J.","family":"Fraites","sequence":"additional","affiliation":[{"name":"Powell Gene Therapy Center, and Departments of Molecular Genetics and Microbiology and Pediatrics, University of Florida College of Medicine,Gainesville, Florida 32610, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy L.","family":"Porvasnik","sequence":"additional","affiliation":[{"name":"Powell Gene Therapy Center, and Departments of Molecular Genetics and Microbiology and Pediatrics, University of Florida College of Medicine,Gainesville, Florida 32610, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Powell Gene Therapy Center, and Departments of Molecular Genetics and Microbiology and Pediatrics, University of Florida College of Medicine,Gainesville, Florida 32610, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Zolotukhin","sequence":"additional","affiliation":[{"name":"Powell Gene Therapy Center, and Departments of Molecular Genetics and Microbiology and Pediatrics, University of Florida College of Medicine,Gainesville, Florida 32610, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise A.","family":"Cloutier","sequence":"additional","affiliation":[{"name":"Powell Gene Therapy Center, and Departments of Molecular Genetics and Microbiology and Pediatrics, University of Florida College of Medicine,Gainesville, Florida 32610, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J.","family":"Byrne","sequence":"additional","affiliation":[{"name":"Powell Gene Therapy Center, and Departments of Molecular Genetics and Microbiology and Pediatrics, University of Florida College of Medicine,Gainesville, Florida 32610, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"237","reference":[{"key":"2021042604401247800_REF1","doi-asserted-by":"crossref","unstructured":"Amalfitano, A., McVie-Wylie, A. J., Hu, H., Dawson, T. L.,Raben, N., Plotz, P. and Chen, Y. T. (1999). Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc. Natl. Acad. Sci. USA96,8861-8866.","DOI":"10.1073\/pnas.96.16.8861"},{"key":"2021042604401247800_REF2","unstructured":"Amalfitano, A., Bengur, A. R., Morse, R. P., Majure, J. M.,Case, L. E., Veerling, D. L., Mackey, J., Kishnani, P., Smith, W.,McVie-Wylie, A. et al. (2001). Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial. Genet. Med.3,132-138."},{"key":"2021042604401247800_REF3","doi-asserted-by":"crossref","unstructured":"Brooks, S. V. and Faulkner, J. A. (1988). Contractile properties of skeletal muscles from young, adult and aged mice. J. Physiol.404,71-82.","DOI":"10.1113\/jphysiol.1988.sp017279"},{"key":"2021042604401247800_REF4","doi-asserted-by":"crossref","unstructured":"Chen, Y. T. and Amalfitano, A. (2000). Towards a molecular therapy for glycogen storage disease type II (Pompe disease). Mol. Med. Today6,245-251.","DOI":"10.1016\/S1357-4310(00)01694-4"},{"key":"2021042604401247800_REF5","doi-asserted-by":"crossref","unstructured":"Cohen, J. C., Morrow, S. L., Cork, R. J., Delcarpio, J. B. and Larson, J. E. (1998). Molecular pathophysiology of cystic fibrosis based on the rescued knockout mouse model. Mol. Genet. Metab.64,108-118.","DOI":"10.1006\/mgme.1998.2683"},{"key":"2021042604401247800_REF6","doi-asserted-by":"crossref","unstructured":"Daly, T. M., Ohlemiller, K. K., Roberts, M. S., Vogler, C. A. and Sands, M. S. (2001). Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. Gene Ther.8,1291-1298.","DOI":"10.1038\/sj.gt.3301420"},{"key":"2021042604401247800_REF7","doi-asserted-by":"crossref","unstructured":"Decrouy, A., Renaud, J. M., Davis, H. L., Lunde, J. A., Dickson,G. and Jasmin, B. J. (1997). Mini-dystrophin gene transfer in mdx4cv diaphragm muscle fibers increases sarcolemmal stability. Gene Ther.4,401-408.","DOI":"10.1038\/sj.gt.3300407"},{"key":"2021042604401247800_REF8","doi-asserted-by":"crossref","unstructured":"Ding, E. Y., Hodges, B. L., Hu, H., McVie-Wylie, A. J., Serra,D., Migone, F. K., Pressley, D., Chen, Y. T. and Amalfitano, A.(2001). Long-term efficacy after [E1-, polymerase-]adenovirus-mediated transfer of human acid-alpha-glucosidase gene into glycogen storage disease type II knockout mice. Hum. Gene Ther.12,955-965.","DOI":"10.1089\/104303401750195917"},{"key":"2021042604401247800_REF9","doi-asserted-by":"crossref","unstructured":"Ding, E., Hu, H., Hodges, B. L., Migone, F., Serra, D., Xu, F.,Chen, Y. T. and Amalfitano, A. (2002). Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction. Mol. Ther.5, 436-446.","DOI":"10.1006\/mthe.2002.0563"},{"key":"2021042604401247800_REF10","doi-asserted-by":"crossref","unstructured":"Douar, A. M., Adebakin, S., Themis, M., Pavirani, A., Cook, T. and Coutelle, C. (1997). Fetal gene delivery in mice by intra-amniotic administration of retroviral producer cells and adenovirus. Gene Ther.4,883-890.","DOI":"10.1038\/sj.gt.3300498"},{"key":"2021042604401247800_REF11","doi-asserted-by":"crossref","unstructured":"Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P.,Waldek, S., Caplan, L., Linthorst, G. E. and Desnick, R. J.(2001). Safety and efficacy of recombinant human alpha-galactosidase A - replacement therapy in Fabry's disease. N. Engl. J. Med.345,9-16.","DOI":"10.1056\/NEJM200107053450102"},{"key":"2021042604401247800_REF12","doi-asserted-by":"crossref","unstructured":"Fraites, T. J., Schleissing, M. R., Shanely, R. A., Walter, G. A., Cloutier, D. A., Zolotukhin, I., Pauly, D. F., Raben, N., Plotz, P. H.,Powers, S. K. et al. (2002). Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol. Ther.5,571-578.","DOI":"10.1006\/mthe.2002.0580"},{"key":"2021042604401247800_REF13","doi-asserted-by":"crossref","unstructured":"Hers, H. G. (1963). Alpha-glucosidase deficiency in generalized glycogen-storage disease (Pompe's disease). Biochem J.86,11.","DOI":"10.1042\/bj0860011"},{"key":"2021042604401247800_REF14","unstructured":"Hirschhorn, R. and Reuser, A. J. (2000). Glycogen Storage Disease Type II: Acid alpha-Glucosidase (Acid Maltase)Deficiency. In The Metabolic and Molecular Basis of Inherited Disease (ed. C. R. Scriver, A. L. Beaudet, W. S. Sly and D. Valle), pp. 3389-3420. New York:McGraw-Hill."},{"key":"2021042604401247800_REF15","doi-asserted-by":"crossref","unstructured":"Hoefsloot, L. H., Willemsen, R., Kroos, M. A.,Hoogeveen-Westerveld, M., Hermans, M. M., Van der Ploeg, A. T., Oostra, B. A. and Reuser, A. J. (1990). Expression and routeing of human lysosomal alpha-glucosidase in transiently transfected mammalian cells. Biochem. J.272,485-492.","DOI":"10.1042\/bj2720485"},{"key":"2021042604401247800_REF16","doi-asserted-by":"crossref","unstructured":"Holzinger, A., Trapnell, B. C., Weaver, T. E., Whitsett, J. A. and Iwamoto, H. S. (1995). Intraamniotic administration of an adenoviral vector for gene transfer to fetal sheep and mouse tissues. Pediatr. Res.38,844-850.","DOI":"10.1203\/00006450-199512000-00004"},{"key":"2021042604401247800_REF17","doi-asserted-by":"crossref","unstructured":"Ibdah, J. A., Paul, H., Zhao, Y., Binford, S., Salleng, K.,Cline, M., Matern, D., Bennett, M. J., Rinaldo, P. and Strauss, A. W.(2001). Lack of mitochondrial trifunctional protein in mice causes neonatal hypoglycemia and sudden death. J. Clin. Invest.107,1403-1409.","DOI":"10.1172\/JCI12590"},{"key":"2021042604401247800_REF18","doi-asserted-by":"crossref","unstructured":"Kakkis, E. D., Muenzer, J., Tiller, G. E., Waber, L., Belmont,J., Passage, M., Izykowski, B., Phillips, J., Doroshow, R., Walot, I. et al. (2001). Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med.344,182-188.","DOI":"10.1056\/NEJM200101183440304"},{"key":"2021042604401247800_REF19","doi-asserted-by":"crossref","unstructured":"Larson, J. E., Morrow, S. L., Happel, L., Sharp, J. F. and Cohen, J. C. (1997). Reversal of cystic fibrosis phenotype in mice by gene therapy in utero. Lancet349,619-620.","DOI":"10.1016\/S0140-6736(05)61567-X"},{"key":"2021042604401247800_REF20","doi-asserted-by":"crossref","unstructured":"Lin, C. Y., Ho, C. H., Hsieh, Y. H. and Kikuchi, T.(2002). Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency. Gene Ther.9,554-563.","DOI":"10.1038\/sj.gt.3301672"},{"key":"2021042604401247800_REF21","doi-asserted-by":"crossref","unstructured":"Lipshutz, G. S., Flebbe-Rehwaldt, L. and Gaensler, K. M.(1999a). Adenovirus-mediated gene transfer in the midgestation fetal mouse. J. Surg. Res.84,150-156.","DOI":"10.1006\/jsre.1999.5588"},{"key":"2021042604401247800_REF22","doi-asserted-by":"crossref","unstructured":"Lipshutz, G. S., Flebbe-Rehwaldt, L. and Gaensler, K. M.(1999b). Adenovirus-mediated gene transfer to the peritoneum and hepatic parenchyma of fetal mice in utero. Surgery126,171-177.","DOI":"10.1016\/S0039-6060(99)70151-0"},{"key":"2021042604401247800_REF23","doi-asserted-by":"crossref","unstructured":"Lipshutz, G. S., Sarkar, R., Flebbe-Rehwaldt, L., Kazazian, H. and Gaensler, K. M. (1999c). Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero. Proc. Natl. Acad. Sci. USA96,13324-13329.","DOI":"10.1073\/pnas.96.23.13324"},{"key":"2021042604401247800_REF24","doi-asserted-by":"crossref","unstructured":"Lipshutz, G. S., Flebbe-Rehwaldt, L. and Gaensler, K. M.(2000). Reexpression following readministration of an adenoviral vector in adult mice after initial in utero adenoviral administration. Mol. Ther.2,374-380.","DOI":"10.1006\/mthe.2000.0136"},{"key":"2021042604401247800_REF25","doi-asserted-by":"crossref","unstructured":"Lipshutz, G. S., Gruber, C. A., Cao, Y., Hardy, J., Contag, C. H. and Gaensler, K. M. (2001). In utero delivery of adeno-associated viral vectors: intraperitoneal gene transfer produces long-term expression. Mol. Ther.3, 284-292.","DOI":"10.1006\/mthe.2001.0267"},{"key":"2021042604401247800_REF26","doi-asserted-by":"crossref","unstructured":"Loser, P., Jennings, G. S., Strauss, M. and Sandig, V.(1998). Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkappaB. J. Virol.72,180-190.","DOI":"10.1128\/JVI.72.1.180-190.1998"},{"key":"2021042604401247800_REF27","doi-asserted-by":"crossref","unstructured":"Martin-Touaux, E., Puech, J. P., Chateau, D., Emiliani, C.,Kremer, E. J., Raben, N., Tancini, B., Orlacchio, A., Kahn, A. and Poenaru, L.(\n          2002). Muscle as a putative producer of acid alpha-glucosidase for glycogenosis type II gene therapy. Hum. Mol. Genet.11,1637-1645.","DOI":"10.1093\/hmg\/11.14.1637"},{"key":"2021042604401247800_REF28","doi-asserted-by":"crossref","unstructured":"Mitchell, M., Jerebtsova, M., Batshaw, M. L., Newman, K. and Ye,X. (2000). Long-term gene transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) vectors. Gene Ther.7,1986-1992.","DOI":"10.1038\/sj.gt.3301332"},{"key":"2021042604401247800_REF29","doi-asserted-by":"crossref","unstructured":"Pan, Y., Zvaritch, E., Tupling, A. R., Rice, W. J., de Leon, S.,Rudnicki, M., McKerlie, C., Banwell, B. L. and MacLennan, D. H.(2003). Targeted disruption of the ATP2A1 gene encoding the sarco(endo)plasmic reticulum Ca2+ ATPase isoform 1 (SERCA1) impairs diaphragm function and is lethal in neonatal mice. J. Biol. Chem.278,13367-13375.","DOI":"10.1074\/jbc.M213228200"},{"key":"2021042604401247800_REF30","doi-asserted-by":"crossref","unstructured":"Pauly, D. F., Johns, D. C., Matelis, L. A., Lawrence, J. H.,Byrne, B. J. and Kessler, P. D. (1998). Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro,and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle. Gene Ther.5,473-480.","DOI":"10.1038\/sj.gt.3300609"},{"key":"2021042604401247800_REF31","doi-asserted-by":"crossref","unstructured":"Pauly, D. F., Fraites, T. J., Toma, C., Bayes, H. S., Huie, M. L., Hirschhorn, R., Plotz, P. H., Raben, N., Kessler, P. D. and Byrne, B. J. (2001). Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease. Hum. Gene Ther.12,527-538.","DOI":"10.1089\/104303401300042447"},{"key":"2021042604401247800_REF32","doi-asserted-by":"crossref","unstructured":"Petrof, B. J., Acsadi, G., Jani, A., Massie, B., Bourdon, J.,Matusiewicz, N., Yang, L., Lochmuller, H. and Karpati, G.(1995). Efficiency and functional consequences of adenovirus-mediated in vivo gene transfer to normal and dystrophic (mdx) mouse diaphragm. Am. J. Respir. Cell. Mol. Biol.13,508-517.","DOI":"10.1165\/ajrcmb.13.5.7576685"},{"key":"2021042604401247800_REF33","doi-asserted-by":"crossref","unstructured":"Petrof, B. J. (1998). Respiratory muscles as a target for adenovirus-mediated gene therapy. Eur. Respir. J.11,492-497.","DOI":"10.1183\/09031936.98.11020492"},{"key":"2021042604401247800_REF34","unstructured":"Pompe, J. C. (1932). Over idiopatische hypertrophie van het hart. Ned. Tijdschr.76, 304."},{"key":"2021042604401247800_REF35","doi-asserted-by":"crossref","unstructured":"Raben, N., Nagaraju, K., Lee, E., Kessler, P., Byrne, B., Lee,L., LaMarca, M., King, C., Ward, J., Sauer, B. and Plotz, P.(1998). Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J. Biol. Chem.273,19086-19092.","DOI":"10.1074\/jbc.273.30.19086"},{"key":"2021042604401247800_REF36","doi-asserted-by":"crossref","unstructured":"Raben, N., Nagaraju, K., Lee, E. and Plotz, P.(2000). Modulation of disease severity in mice with targeted disruption of the acid alpha-glucosidase gene. Neuromuscul. Disord.10,283-291.","DOI":"10.1016\/S0960-8966(99)00117-0"},{"key":"2021042604401247800_REF37","doi-asserted-by":"crossref","unstructured":"Raben, N., Plotz, P. and Byrne, B. J. (2002). Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr. Mol. Med.2,145-166.","DOI":"10.2174\/1566524024605789"},{"key":"2021042604401247800_REF38","doi-asserted-by":"crossref","unstructured":"Schachtner, S., Buck, C., Bergelson, J. and Baldwin, H.(1999). Temporally regulated expression patterns following in utero adenovirus-mediated gene transfer. Gene Ther.6,1249-1257.","DOI":"10.1038\/sj.gt.3300939"},{"key":"2021042604401247800_REF39","doi-asserted-by":"crossref","unstructured":"Schneider, H., Adebakin, S., Themis, M., Cook, T., Douar, A. M.,Pavirani, A. and Coutelle, C. (1999). Therapeutic plasma concentrations of human factor IX in mice after gene delivery into the amniotic cavity: a model for the prenatal treatment of haemophilia B.J. Gene Med.1,424-432.","DOI":"10.1002\/(SICI)1521-2254(199911\/12)1:6<424::AID-JGM70>3.0.CO;2-Q"},{"key":"2021042604401247800_REF40","doi-asserted-by":"crossref","unstructured":"Schneider, H., Muhle, C., Douar, A. M., Waddington, S., Jiang,Q. J., von der, M. K., Coutelle, C. and Rascher, W. (2002). Sustained delivery of therapeutic concentrations of human clotting factor IX -a comparison of adenoviral and AAV vectors administered in utero. J. Gene Med.4,46-53.","DOI":"10.1002\/jgm.233"},{"key":"2021042604401247800_REF41","doi-asserted-by":"crossref","unstructured":"Song, S., Embury, J., Laipis, P. J., Berns, K. I., Crawford, J. M. and Flotte, T. R. (2001). Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Ther.8,1299-1306.","DOI":"10.1038\/sj.gt.3301422"},{"key":"2021042604401247800_REF42","doi-asserted-by":"crossref","unstructured":"Srivastava, A. (2002). Obstacles to human hematopoietic stem cell transduction by recombinant adeno-associated virus 2 vectors. J. Cell Biochem. Suppl.38, 39-45.","DOI":"10.1002\/jcb.10053"},{"key":"2021042604401247800_REF43","doi-asserted-by":"crossref","unstructured":"Staib, J. L., Swoap, S. J. and Powers, S. K.(2002). Diaphragm contractile dysfunction in MyoD gene-inactivated mice. Am. J. Physiol Regul. Integr. Comp. Physiol.283,R583-R590.","DOI":"10.1152\/ajpregu.00080.2002"},{"key":"2021042604401247800_REF44","doi-asserted-by":"crossref","unstructured":"Tsujino, S., Kinoshita, N., Tashiro, T., Ikeda, K., Ichihara,N., Kikuchi, H., Hagiwara, Y., Mizutani, M., Kikuchi, T. and Sakuragawa,N. (1998). Adenovirus-mediated transfer of human acid maltase gene reduces glycogen accumulation in skeletal muscle of Japanese quail with acid maltase deficiency. Hum. Gene Ther.9,1609-1616.","DOI":"10.1089\/hum.1998.9.11-1609"},{"key":"2021042604401247800_REF45","doi-asserted-by":"crossref","unstructured":"Van den Hout, J. M., Reuser, A. J., de Klerk, J. B., Arts, W. F., Smeitink, J. A. and Van der Ploeg, A. T. (2001). Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. J. Inherit. Metab. Dis.24,266-274.","DOI":"10.1023\/A:1010383421286"},{"key":"2021042604401247800_REF46","doi-asserted-by":"crossref","unstructured":"Wisselaar, H. A., Kroos, M. A., Hermans, M. M., van Beeumen, J. and Reuser, A. J. (1993). Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J. Biol. Chem.268,2223-2231.","DOI":"10.1016\/S0021-9258(18)53985-5"},{"key":"2021042604401247800_REF47","doi-asserted-by":"crossref","unstructured":"Xiao, W., Berta, S. C., Lu, M. M., Moscioni, A. D., Tazelaar, J. and Wilson, J. M. (1998). Adeno-associated virus as a vector for liver-directed gene therapy. J. Virol.72,10222-10226.","DOI":"10.1128\/JVI.72.12.10222-10226.1998"},{"key":"2021042604401247800_REF48","doi-asserted-by":"crossref","unstructured":"Xu, L., Daly, T., Gao, C., Flotte, T. R., Song, S., Byrne, B. J., Sands, M. S. and Parker, P. K. (\n          2001). CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum. Gene Ther.12,563-573.","DOI":"10.1089\/104303401300042500"},{"key":"2021042604401247800_REF49","doi-asserted-by":"crossref","unstructured":"Zhou, Q., Chu, P. H., Huang, C., Cheng, C. F., Martone, M. E.,Knoll, G., Shelton, G. D., Evans, S. and Chen, J. (2001). Ablation of Cypher, a PDZ-LIM domain Z-line protein, causes a severe form of congenital myopathy. J. Cell Biol.155,605-612.","DOI":"10.1083\/jcb.200107092"},{"key":"2021042604401247800_REF50","doi-asserted-by":"crossref","unstructured":"Zolotukhin, S., Potter, M., Zolotukhin, I., Sakai, Y., Loiler,S., Fraites, T. J., Jr, Chiodo, V. A., Phillipsberg, T., Muzyczka, N.,Hauswirth, W. W. et al. (2002). Production and purification of serotype 1, 2 and 5 recombinant adeno-associated viral vectors. Methods28,158-167.","DOI":"10.1016\/S1046-2023(02)00220-7"}],"container-title":["Development"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.biologists.com\/dev\/article-pdf\/131\/12\/3007\/1505244\/3007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/journals.biologists.com\/dev\/article-pdf\/131\/12\/3007\/1505244\/3007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T05:25:32Z","timestamp":1619414732000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.biologists.com\/dev\/article\/131\/12\/3007\/42244\/Rescue-of-enzyme-deficiency-in-embryonic-diaphragm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,15]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2004,6,15]]}},"URL":"https:\/\/doi.org\/10.1242\/dev.01169","relation":{},"ISSN":["1477-9129","0950-1991"],"issn-type":[{"value":"1477-9129","type":"electronic"},{"value":"0950-1991","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6,15]]}}}